Search Results

You are looking at 1 - 10 of 21 items for :

  • Pediatrics and Juvenile Medicine x
Clear All
Open access

Pablo Ajler, Alvaro Campero, Federico Landriel, Ezequiel Goldschmidt, Santiago Hem and Antonio Carrizo

.1097/00006123-200207000-00020 Lasio G Ferroli P Felisati G Broggi G Image-guided endoscopic transnasal removal of recurrent pituitary adenomas Neurosurgery 51 132 137 2002 [13] Leach P, Abou-Zeid AH, Kearney T, Davis J, Trainer PJ, Gnanalingham KK: Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve. Neurosurgery 67:1205-1212, 2010 10.1227/NEU.0b013e3181ef25c5 Leach P Abou-Zeid AH Kearney T Davis J Trainer PJ Gnanalingham KK Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve Neurosurgery 67 1205 1212 2010 [14] Spaziante R

Open access

F. Salle, A. Jaume, G. Castelluccio and E. Spagnuolo

recurrent or residual lesions after coiling [ 9 ]. The ISAT revealed that rebleeding rates are 0,3% per year greater with coil embolization. Early rebleeding (during the first 30 days after treatment) was the most frequent: 1,9% for coiling vs 0,7% for clipping. Lanzino et al. mention that rebleeding rate in the first month after coil embolization might reach 2,7% 10. A follow up study of the patients treated in the ISAT was performed to compare the frequency and consequences of aneurysm recurrence. Retreatment was performed in 17.4% of patients after primary

Open access

A. Dhanya Mackeen, John W. Ross, Alexandria Betz, Wen Feng, Jay J. Bringman and Michael J. Paglia

restriction at term: Randomised equivalence trial (DIGITAT). BMJ. 2010;341:c7087. doi: 10.1136/bmj.c7087 [doi]. 7. Spong CY, Mercer BM, D’alton M, Kilpatrick S, Blackwell S, Saade G. Timing of indicated late-preterm and early-term birth. Obstet Gynecol. 2011;118(2 Pt 1):323-333 [Review, Guideline]. 8. Predanic M, Kolli J, Yousefzadeh P, Pennisi J. Disparate blood flow patterns in parallel umbilical arteries. Obstet Gynecol. 1998;91(5 Pt 1):757-760. 9. Predanic M, Perni SC. Antenatal assessment of discordant umbilical arteries

Open access

Skuteczne leczenie ibrutynibem chorego na przewlekłą białaczką limfocytową z obecnością delecji 17p – opis przypadku

A 62-year-old patient with CLL and 17p deletion successfully treated with ibrutinib – a case report

Bożena Sokołowska, Ewa Wasik- Szczepanek, Sylwia Chocholska and Marek Hus

ibrutynibem) Grudzień 2017 (32 mc leczenia ibrutynibem) Leukocyty K/μl (4,0-10,0) 23,7* 50,52* 2,95* 2,94* 9,25 7,95 Limfocyty K/μl (0,8-4,3) 19,43* 42,61* 1,45 0,92 2,87 3,36 Granulocyty K/μl (2,8-6,8) 3,97 2,44* 1,33* 1,85* 5,69 3,78 Hemoglobina g/dl (13,0-18,0) 13,5 12,0* 10,9* 11,8* 15,1 15,9 Trombocyty K/μl (120-400) 384 373 408 141 290 182 Dehydrogenaza mleczanowa (LDH) IU/l (10-480) 253 507* 202 534* 304 164 β2 mikroglobulina mg/l (0,7-2,4 ) nb nb nb 3

Open access

Przewlekłe leczenie przeciwkrzepliwe

Komentarz do artykułu „Sulodeksyd w zapobieganiu nawrotom zakrzepicy żył głębokich – badanie SURVET”

Krystyna Zawilska

. W innej próbie klinicznej w grupie ~680 pacjentów leczonych dabigatranem stwierdzono istotne zmniejszenie częstości nawrotów ŻChZZ, ale częstość powikłań krwotocznych była znamiennie większa niż w odpowiednio dobranej grupie kontrolnej otrzymującej placebo [ 8 ]. Apiksaban w badaniu AMPLIFY-EXTENSION w obu dawkach (2,5 mg 2 x/dobę i 5 mg 2 x/dobę) wykazał podobną, bardzo dobrą skuteczność i bezpieczeństwo w ciągu 12. miesięcznego leczenia w grupach po ~800 pacjentów, włączony po zakończeniu 6. lub 12. miesięcznego stosowania warfaryny [ 9 ]. W badaniu ENSTEIN

Open access

Katarzyna Leszczyńska, Krzysztof Preis, Maria Respondek-Liberska, Maciej Słodki, Dennis Wood, Stuart Weiner, Ulli Gembruch, Giusseppe Rizzo, Reuven Achiron, Jay D Pruetz, Mark Sklansky, Bettina Cuneo, Birgit Arabin and Isaac Blickstein

Obstet Gynecol. 2008 Nov;199(5):514.e1-8. doi: 10.1016/j.ajog.2008.03.050. Epub 2008 Jun 4 3. Arabin B, Gembruch U, von Eyck J. Registration of fetal behaviour in multiple pregnancy. J Perinat Med. 1993;21(4):285-94. 4. Rychik J, Ayres N, Cuneo B, Gotteiner N, Hornberger L, Spevak F, Van Der Veld M.: American Society of Echocardiography Guidelines and Standards for Performance of the Fetal Echocardiogram. J Am Soc Echocardiogr 2004,17:803-10 5. Allan L, Dangel J, Fesslova V, Marek J, Mellander M, Oberhänsli I, Oberhoffer R, Sharland G, Simpson J

Open access

Jiayu Huang, Yun Lian and Sixuan Qian

-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-3279. 10.1182/blood-2006-03-009142 Garcia-Manero G Kantarjian HM Sanchez-Gonzalez B Phase 1/2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemia Blood 2006 108 3271 3279 [31] Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. Journal of clinical oncology: official journal of the American Society

Open access

Samia Abd El-Moneim Ebied, Nadia Aly Sadek, Nadia El-Sayed Zaki, Samir Ali Abd El- Kaream and Heba Khafagui Ahmed El Kashif

/l) Range 9.50-10.60 7.10-9.60 4.30-9.70 Mean ± SE 10.20 ± 0.07 8.53 ± 0.14 8.28 ± 0.49 P1 p 1 < 0.001 * p 2 < 0.001 * Phosphorus (meq/l) Range 4.80-5.30 2.70-5.10 2.50-4.60 Mean ± SE 5.04 ± 0.03 3.95 ± 0.10 3.90 ± 0.22 P1 p 1 < 0.001 * p 2 < 0.001 * p 1 : p value for comparing between control and patients *: Statistically significant at p ≤ 0.05 Hematological Results Mean values of WBC count (x10e9), Platelets count (x10e9) and Hemoglobin concentration (g/dl) in normal

Open access

Monika Adamska, Anna Komosa, Tatiana Mularek, Joanna Rupa-Matysek and Lidia Gil

] Palladini, G., et al., Identification of amyloidogenic light chains requires the combination of serum - free light chain assay with immunofixation of serum and urine . Clin Chem, 2009. 55 (3): p. 499-504. 10.1373/clinchem.2008.117143 Palladini G. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine Clin Chem 2009 55 3 499 504 [25] Campo, E., et al., The 2008 WHO classification of lymphoid neoplasms and beyond : evolving concepts and practical applications . Blood, 2011. 117 (19

Open access

Agnieszka Szymczyk, Aleksandra Nowaczyńska, Maciej Korpysz, Helena Donica, Agnieszka Bojarska-Junak, Monika Długosz-Danecka, Waldemar Tomczak, Ewa Wąsik-Szczepanek and Iwona Hus

characteristics of the study group and prognostic factors are presented in table I . Table I Clinical and laboratory characteristics of the study group Age Md (years) ± SD (min.-max.) 64.4 ± 9.5 (44–85) Sex female 31 man 28 Clinical stage according to the Rai classification early (0-I) 37 advanced (II-IV ) 22 CD38 (cut-off point 30%) positive 16 negative 43 ZAP-70 (cut-off point 20%) positive 18 negative 41 Cytogenetic aberrations del17p 9/25 del11q 11/25 WBC (G/l) M ± SD (min